HIV drug resistance to integrase inhibitors in low- and middle-income countries.
作者信息
Fokam Joseph, Inzaule Seth, Colizzi Vittorio, Perno Carlo-Federico, Kaseya Jean, Ndembi Nicaise
机构信息
Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon.
Faculty of Health Sciences, University of Buea, Buea, Cameroon.
出版信息
Nat Med. 2024 Mar;30(3):618-619. doi: 10.1038/s41591-023-02763-0.
Abstract
摘要
相似文献
1
HIV drug resistance to integrase inhibitors in low- and middle-income countries.
Nat Med. 2024 Mar;30(3):618-619. doi: 10.1038/s41591-023-02763-0.
2
Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man.
J Antimicrob Chemother. 2023 Jul 5;78(7):1802-1803. doi: 10.1093/jac/dkad135.
3
Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries.
Viruses. 2024 Nov 29;16(12):1853. doi: 10.3390/v16121853.
4
[Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
Med Monatsschr Pharm. 2013 Dec;36(12):448-59; quiz 461-2.
5
Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.
6
Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
7
What if HIV were unable to develop resistance against a new therapeutic agent?
BMC Med. 2013 Nov 22;11:249. doi: 10.1186/1741-7015-11-249.
8
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
Diagn Microbiol Infect Dis. 2022 Feb;102(2):115574. doi: 10.1016/j.diagmicrobio.2021.115574. Epub 2021 Oct 22.
9
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
J Virol. 2015 Dec;89(23):12002-13. doi: 10.1128/JVI.02131-15. Epub 2015 Sep 16.
10
Primary resistance to integrase inhibitors in Shenzhen.
J Antimicrob Chemother. 2023 Feb 1;78(2):546-549. doi: 10.1093/jac/dkac442.
引用本文的文献
1
Confronting Dual Therapeutic Hurdles in Advanced HIV: A Case Report on INSTIs Resistance and Talaromyces marneffei Coinfection.
Int Med Case Rep J. 2025 Aug 22;18:1071-1075. doi: 10.2147/IMCRJ.S537404. eCollection 2025.
2
Do we need routine integrase resistance testing before starting antiretroviral therapy?
Lancet HIV. 2025 Jun 17. doi: 10.1016/S2352-3018(25)00108-0.
3
Treatment of Advanced HIV in the Modern Era.
Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181-1.
4
The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.
AIDS. 2025 Jul 15;39(9):1161-1177. doi: 10.1097/QAD.0000000000004202. Epub 2025 Apr 15.
5
Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique.
AIDS Res Ther. 2025 Jan 30;22(1):8. doi: 10.1186/s12981-025-00708-w.
6
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae365. doi: 10.1093/ofid/ofae365. eCollection 2024 Jul.
本文引用的文献
1
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X. Epub 2023 Oct 10.
2
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.
3
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0138622. doi: 10.1128/aac.01386-22. Epub 2023 Apr 18.
4
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Antimicrob Resist Infect Control. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2.
5
Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.
N Engl J Med. 2019 Aug 29;381(9):887-889. doi: 10.1056/NEJMc1806554.
6
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Lancet HIV. 2018 Jul;5(7):e400-e404. doi: 10.1016/S2352-3018(18)30093-6. Epub 2018 Jun 5.
7
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.
Zotero 插件